Viking Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -94 | |||
EBITDA | -183,098 | -127,865 | -158,240 | -157,568 |
EBIT | -183,098 | -128,022 | -158,325 | -157,662 |
Net Income | -183,186 | -128,022 | -158,325 | -157,662 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -138,194 | -125,172 | -113,976 | -85,290 |
Cash | 677,609 | 125,750 | 118,116 | 165,810 |
Basic Shares | 118,050 | 115,917 | 115,568 | 114,005 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -431 | -346 | -292 | -291 |
EBITDA | -359,152 | -109,523 | -100,827 | -68,517 |
EBIT | -359,583 | -109,869 | -100,827 | -68,808 |
Net Income | -359,639 | -109,963 | -85,895 | -68,867 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | 10,519 | |||
Free Cash Flow | -278,685 | -87,790 | -73,376 | -48,397 |
Cash | 165,810 | 26,676 | 55,516 | 36,632 |
Basic Shares | 112,667 | 109,037 | 94,347 | 76,834 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$1.55 |
2026-06-30 | -$1.10 |
2026-03-31 | -$1.37 |
2025-12-31 | -$1.38 |